Bicycle Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Bicycle Therapeutics stock has a consensus rating of "Buy" and an average price target of $12.63. The average 1-year stock price forecast is 215.75% higher than the current stock price, while the lowest is $5.00 (+25.00%) and the highest is $36 (+800.00%).

Price Target: $12.63 (+215.75%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$12.63	$10	$36
Change	+25.00%	+215.75%	+150.00%	+800.00%

Analyst Ratings

The average analyst rating for Bicycle Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	5	5	5	5
Buy	2	2	2	2	2	2
Hold	4	4	4	4	4	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	11	11	11	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ami Fadia Needham	Needham	Buy Maintains $15	Buy	Maintains	$15	+275.00%	May 22, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Hold Maintains $12	Hold	Maintains	$12	+200.00%	May 18, 2026
Gregory Renza Truist Financial	Truist Financial	Hold Maintains $8 → $7	Hold	Maintains	$8 → $7	+75.00%	May 1, 2026
Maury Raycroft Jefferies	Jefferies	Buy Maintains $13 → $12	Buy	Maintains	$13 → $12	+200.00%	Apr 30, 2026
Tara Bancroft TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Apr 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

18.24M

from 72.59M

-74.88%

from 72.59M

Revenue Next Year

14.11M

from 18.24M

-22.61%

from 18.24M

EPS This Year

-2.28

from -3.16

EPS Next Year

-2.13

from -2.28

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	11.70M	14.46M	26.98M	35.28M	72.59M	18.24M
Revenue Growth	12.58%	23.65%	86.52%	30.76%	105.77%	-74.88%
Gross Profit	-33.18M	-67.15M	-120.68M	-129.59M	-156.50M	18.24M
Gross Margin	-283.69%	-464.26%	-447.34%	-367.36%	-215.60%	100.00%
Operating Income	-65.62M	-116.65M	-189.95M	-208.77M	-242.87M	-178.81M
Net Income	-66.82M	-112.72M	-180.66M	-169.03M	-218.96M	-153.65M
EPS	-	-	-	-	-3.16	-2.28
Free Cash Flow	-19.99M	-57.51M	-75.43M	-104.12M	-121.57M	-118.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	40.0M
Avg	18.2M
Low	3.1M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-44.9%
Avg	-74.9%
Low	-95.7%

EPS Forecast

EPS	2026	2027	2028
High	-1.30
Avg	-2.28
Low	-2.86

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-